Hepatitis C virus (HCV) coinfection remains a significant risk factor for mortality among people living with human immunodeficiency virus (PLwH) after initiating antiretroviral therapy (ART), a recent study found. Researchers analyzed data from the Women’s Interagency HIV Study and the Multicenter AIDS Cohort Study. Participants included those who had prevalent HIV or seroconverted during follow-up, and all were antiretroviral-naïve and acquired immunodeficiency syndrome (AIDS)-free prior to their first visits after October 1, 1994. Follow-up lasted 10 years. Among the findings:
- There were 3,056 eligible participants (58% female, 18% had HCV).
- The estimated 10-year all-cause mortality risk in which no PLwH had HCV was 10.4%.
- The 10-year mortality risk difference for HCV infection was 4.3% (risk ratio [RR] 1.4).
- The risk difference for direct-acting antiviral (DAA) treatment was ‒3.8% (RR 0.8).
Breskin A, Westreich D, Cole SR, et al. The effects of hepatitis C infection and treatment on all-cause mortality among people living with human immunodeficiency virus. [Published online ahead of print October 12, 2018]. Clin Infect Dis. doi:10.1093/cid/ciy588.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al